CLIA Kit for Bone Morphogenetic Protein 2 (BMP2) Homo sapiens (Human) Sandwich CLIA

BMP2A; BMP-2A; Hemochromatosis Modifier

  • Product No.SCA013Hu
  • Organism SpeciesHomo sapiens (Human)
  • Sample TypeSerum, plasma and other biological fluids
  • Test MethodDouble-antibody Sandwich
  • Assay Length2h, 40min
  • Detection Range46.88-3000pg/mL
  • SensitivityThe minimum detectable dose of this kit is typically less than 1.77pg/mL.
  • Specificity This assay has high sensitivity and excellent specificity for detection of Bone Morphogenetic Protein 2 (BMP2).
    No significant cross-reactivity or interference between Bone Morphogenetic Protein 2 (BMP2) and analogues was observed.
  • ApplicationsChemiluminescent immunoassay for Antigen Detection
  • DownloadInstruction Manual
  • Format 48T96T 96T*5 96T*10 96T*100
  • FOB US$ 588US$ 840 US$ 3780 US$ 7140 US$ 58800
  • CLIA Kit for Bone Morphogenetic Protein 2 (BMP2) Package and Components
  • CLIA Kit for Bone Morphogenetic Protein 2 (BMP2) Package and Components
  • CLIA Kit for Bone Morphogenetic Protein 2 (BMP2) Results demonstration
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Bone Morphogenetic Protein 2 (BMP2) and the recovery rates were calculated by comparing the measured value to the expected amount of Bone Morphogenetic Protein 2 (BMP2) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 78-102 83
EDTA plasma(n=5) 79-91 87
heparin plasma(n=5) 91-104 101

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Bone Morphogenetic Protein 2 (BMP2) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Bone Morphogenetic Protein 2 (BMP2) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Bone Morphogenetic Protein 2 (BMP2) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 80-99% 78-92% 89-99% 87-96%
EDTA plasma(n=5) 78-99% 86-94% 84-101% 94-105%
heparin plasma(n=5) 79-93% 85-94% 81-91% 91-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Bone Morphogenetic Protein 2 (BMP2)

Test principle

The microtiter plate provided in this kit has been pre-coated with an antigen. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated secondary antibody. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Bone Morphogenetic Protein 2 (BMP2) level in the sample or standard.

GIVEAWAYS

Reference

  • Journal of Applied ToxicologyChronic exposure to low concentrations of strontium 90 affects bone physiology but not the hematopoietic system in miceWiley: Source
  • PLoS ONEA Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic ApproachesPlosone: Source
  • Medical Journal of Chinese People&#039;s Liberation ArmyEffect of transplantation of BMP-2-induced bone marrow mesenchymal stem cells on myocardial infarction of rats after reperfusionSource
  • PLOS ONEPDGF-AA promotes osteogenic differentiation and migration of mesenchymal stem cell by down-regulating PDGFRα and derepressing BMP-Smad1/5/8 signalingPubmed:25470749
  • Eur J PharmacolNegative effect of serotonin–norepinephrine reuptake inhibitor therapy on rat bone tissue after orchidectomyPubMed: 25934570
  • PharmacologyEffect of Mirtazapine on Rat Bone Tissue after OrchidectomyPubMed: 25871861
  • Journal of Cellular BiochemistryTitanium with Nanotopography Induces Osteoblast Differentiation by Regulating Endogenous Bone Morphogenetic Protein Expression and Signaling PathwayPubMed: 26681207